Human epidermal growth factor receptor 2 (HER2), anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) would be familiar terms for the people who have been paying a close attention to those news articles regarding anticancer treatment.

Depending on the genetic mutation a patient has, effective treatment varies while treatments specifically targeting these genes are emerging one after another. In particular, such changes are apparent in the anticancer treatment scene.

In the age of precise medicine, the South Korean government has stated in 2016 the customized medicine would be realized through precise medicine and that the government would also seek new emerging